Methods of Using IL-1beta Compounds

摘要

This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

主权项

1: A method of treating Familial Mediterranean Fever (FMF), comprising administering to a patient in need thereof an effective amount of an IL-1beta antibody comprising:
a) an immunoglobulin heavy chain variable domain (VH) comprising the amino acid sequence set forth as SEQ ID NO:1; b) an immunoglobulin light chain variable domain (VL) comprising the amino acid sequence set forth as SEQ ID NO:2; c) an immunoglobulin VH comprising the amino acid sequence set forth as SEQ ID NO: 1 and an immunoglobulin VL comprising the amino acid sequence set forth as SEQ ID NO: 2; or d) the three CDRs of the VH as set forth as SEQ ID NO:1 and the three CDRs of the VL as set forth as SEQ ID NO:2.